LEASE AGREEMENTLease Agreement • May 6th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances) • Georgia
Exhibit 10.17 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT, dated as of FEBRUARY 20, 2004, is between Inhibitex, Inc., a Delaware corporation (the "Company"), and DAVID WONNACOTT (the "Executive"). WHEREAS, the Company and the...Executive Employment Agreement • March 3rd, 2004 • Inhibitex Inc
COVER PAGEAgreement • May 25th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances) • District of Columbia
Warrant No. PD Number of SharesInhibitex Inc • March 3rd, 2004 • Delaware
LOAN AGREEMENTLoan Agreement • March 28th, 2005 • Inhibitex Inc • Biological products, (no disgnostic substances) • Georgia
COMMON STOCKInhibitex Inc • March 3rd, 2004 • Minnesota
Exhibit 10.12 INDEMNITY AGREEMENT This Indemnity Agreement (this "Agreement") is made and entered into as of the _____ day of _______, 2004 by and between INHIBITEX, INC., a Delaware corporation ("Indemnitor") and ___________ ("Indemnitee"). WHEREAS,...Indemnity Agreement • March 3rd, 2004 • Inhibitex Inc • Delaware
Exhibit 10.32 [ATHEROGENICS LOGO] SUBLEASE AGREEMENT - Amended and Restated 1. Parties. This sublease agreement (the "Sublease"), entered into this 1st day of January, 2001 is made by and between ATHEROGENICS, INC., a Corporation formed under the laws...Sublease Agreement • March 3rd, 2004 • Inhibitex Inc
AMENDMENT NO. 2 TO THE LICENSE AGREEMENT BETWEEN THE TEXAS A&M UNIVERSITY SYSTEM AND INHIBITEX, INC.License Agreement • March 3rd, 2004 • Inhibitex Inc
BETWEENLicense Agreement • May 25th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances)
COMMON STOCKInhibitex Inc • May 6th, 2004 • Biological products, (no disgnostic substances) • New York
Agreement" means this agreement incorporating Schedules 1 (Product Specification), 2 (Services), 3 (Price and Terms of Payment) and Schedule 4 (Inhibitex Patents) as amended or varied from time to time by written agreement of the parties;Agreement • December 10th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances) • New York
EXHIBIT 10.40 LOAN AGREEMENT DECEMBER 28, 2004 Inhibitex, Inc. Alpharetta, Georgia Ladies and Gentlemen: This letter constitutes the agreement (this "AGREEMENT") between the Borrower and the Lender named below with respect to the Loan described below:...Loan Agreement • March 28th, 2005 • Inhibitex Inc • Biological products, (no disgnostic substances) • Georgia
BETWEENExclusive License Agreement • March 3rd, 2004 • Inhibitex Inc • Georgia
SUBLEASE BETWEENInhibitex Inc • March 3rd, 2004
RECITALS:Employee Stock Option Agreement • February 14th, 2006 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • Delaware
WITNESSETHLicense Agreement • May 25th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances) • Iowa
betweenLicence Agreement • May 25th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances)
RECITALSProduction Agreement • May 25th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances)
Exhibit 10.37 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY AN ASTERISK, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED....Agreement for Services • May 6th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances) • New York
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT INHIBITEX, INC. 9005 Westside Parkway Alpharetta, GA 30004 Ladies & Gentlemen: The undersigned, _________________________________(the "Investor"), hereby confirms its agreement with you as follows: 1. This...Securities Purchase Agreement • August 23rd, 2005 • Inhibitex Inc • Biological products, (no disgnostic substances) • New York
AGREEMENT AND PLAN OF MERGER Dated as of January 7, 2012 Among BRISTOL-MYERS SQUIBB COMPANY, INTA ACQUISITION CORPORATION and INHIBITEX, INC.Agreement and Plan of Merger • January 10th, 2012 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • Delaware
This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of January 7, 2012, is entered into by and among Bristol-Myers Squibb Company, a Delaware corporation (“Parent”), Inta Acquisition Corporation, a Delaware corporation and a wholly-owned Subsidiary of Parent (“Sub”), and Inhibitex, Inc., a Delaware corporation (the “Company”).
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • April 13th, 2011 • Inhibitex, Inc. • Biological products, (no disgnostic substances)
THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), approved by Board as of December 21, 2010 (the “Effective Date”), is between Inhibitex, Inc., a Delaware corporation (the “Company”), and Geoff Henson (the “Executive”).
BY AND BETWEENLoan and Security Agreement • March 3rd, 2004 • Inhibitex Inc • Georgia
ARTICLE I DEFINITIONSInhibitex Inc • March 3rd, 2004 • California
11,463,415 Shares INHIBITEX, INC. Common Stock ($0.001 Par Value) EQUITY UNDERWRITING AGREEMENTUnderwriting Agreement • April 7th, 2011 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • New York
Inhibitex, Inc.., a Delaware corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as representative (the “Representative” or “you”) an aggregate of 11,463,415 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value (the “Common Stock”). The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names in Schedule I hereto. The Company also proposes to sell at the Underwriters’ option an aggregate of up to 1,719,512 additional shares of the Company’s Common Stock (the “Option Shares”) as set forth below. The Firm Shares and the Option Shares (to the extent the aforementioned option is exercised) are herein collectively called the “Shares.”
INHIBITEX INCAgreement • January 19th, 2005 • Inhibitex Inc • Biological products, (no disgnostic substances) • New York
INHIBITEX, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementInhibitex, Inc. • November 24th, 2010 • Biological products, (no disgnostic substances) • New York
Inhibitex, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with McNicoll, Lewis & Vlak LLC (“MLV”), as follows:
EXHIBIT 10.1 SECOND AMENDMENT TO FOURTH AMENDED AND RESTATED MASTER RIGHTS AGREEMENT This Second Amendment ("Amendment") to the Fourth Amended and Restated Master Rights Agreement ("Master Agreement") dated as of December 19, 2003 among Inhibitex,...Master Rights Agreement • August 16th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances)
Exhibit 10.27 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. PLASMA...Plasma Supply Agreement • March 3rd, 2004 • Inhibitex Inc • New York
EMPLOYEE STOCK OPTION AGREEMENTEmployee Stock Option Agreement • November 9th, 2007 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • Delaware
EMPLOYEE STOCK OPTION AGREEMENT, dated as of (this “Agreement”), by and between INHIBITEX, INC., a Delaware corporation (the “Company”), and ___(the “Optionee”).
TENDER AND SUPPORT AGREEMENTTender and Support Agreement • January 10th, 2012 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • Delaware
This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of January 7, 2012, is by and among Bristol-Myers Squibb Company, a Delaware corporation (“Parent”), Inta Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (“Sub”), Inhibitex, Inc., a Delaware corporation (the “Company”) and each of the Persons set forth on Schedule A hereto (each, a “Stockholder”). The Company shall only be a party to this Agreement for purposes of Sections 4.7 through 4.10 and Article V of this Agreement.
PARENT VOTING AGREEMENTParent Voting Agreement • April 13th, 2007 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS PARENT VOTING AGREEMENT ( this “Agreement”) is entered into as of April 9, 2007, by and between FERMAVIR PHARMACEUTICALS, INC., a Florida corporation (the “Company”), and certain Stockholders of INHIBITEX, INC., a Delaware corporation (“Parent”), whose signatures appear on the signature pages to this Agreement (each a “Stockholder”). Capitalized terms used and not otherwise defined herein shall have the meanings given to such terms in the Merger Agreement (as defined herein).
COMPANY VOTING AGREEMENTCompany Voting Agreement • April 13th, 2007 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • Delaware
COMPANY VOTING AGREEMENT (this “Agreement”) dated as of April , 2007, by and between INHIBITEX, INC., a Delaware corporation (“Parent”), and the Stockholders of FERMAVIR PHARMACEUTICALS, INC., a Florida corporation (the “Company”), whose signatures appear on the signature pages to this Agreement (each a “Stockholder”). Capitalized terms used and not otherwise defined herein shall have the meanings given to such terms in the Merger Agreement (as defined herein).
SECURITY AGREEMENTSecurity Agreement • April 13th, 2007 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • New York
This SECURITY AGREEMENT (this “Agreement”), dated as of April 9, 2007, by FERMAVIR PHARMACEUTICALS, INC., a Florida corporation (“FPI”) and FERMAVIR RESEARCH, INC., a Delaware corporation (“FRI”, each of FPI and FRI is referred to herein individually as a “Grantor” and collectively as the “Grantors”), and INHIBITEX, INC., a Delaware corporation (the “Purchaser” or the “Collateral Agent”), as Collateral Agent on behalf of the Holders (as defined herein).
